Work

Abstract CT241: ENVOY-001: A phase 1, multicenter, open-label study of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in HLA-A*02+ patients with HPV16+ recurrent, locally advanced, or metastatic solid tumors

Year: 2022

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2022-ct241

Authors: Victoria Villaflor, Rajwanth Veluswamy, Elena Garralda, Richard Maziarz, Emese Zsiros, Anthony Shields, Mariano Ponz-Sarvise, Martijn Lolkema, Mehdi Brahmi, Julia Jennings, Nathan Miselis, Lindsay Moore, Katarina Blagovic, Rui-Ru Ji, Scott Loughhead, Ricardo Zwirtes, Sandip Patel

Institutions: City Of Hope National Medical Center, Vall d'Hebron Institute of Oncology, Oregon Health & Science University, Roswell Park Comprehensive Cancer Center, The Barbara Ann Karmanos Cancer Institute, Centro de Investigación Médica Aplicada, Erasmus MC, Centre Léon Bérard, SQZ Biotech (United States), UC San Diego Health System

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4282967344

Cites:

Cited by:

Related to: 10